Cellectar Biosciences, Inc. CLRB
Cellectar Biosciences, Inc. (Nasdaq: CLRB) is an oncology drug developer. Its lead program, iopofosine I 131, is in Phase 2 for relapsed/refractory Waldenstrom macroglobulinemia. Its next catalyst on record is iopofosine I 131: Phase 3 randomized confirmatory study in WM launch/first patient (precondition for accelerated-approval NDA) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: iopofosine I 131 — Phase 3 randomized confirmatory study in WM launch/first patient (precondition for accelerated-approval NDA) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| iopofosine I 131 (CLOVER WaM, Phase 2b pivotal single-arm) | relapsed/refractory Waldenstrom macroglobulinemia | radiopharmaceutical | Phase 2 |
| iopofosine I 131 (CLOVER-1 Phase 2b) | relapsed/refractory multiple myeloma and CNS lymphoma | radiopharmaceutical | Phase 2 |
| iopofosine I 131 (CLOVER-2) | pediatric high-grade glioma | radiopharmaceutical | Phase 1 |
| CLR 121125 (CLR 125) | triple-negative breast cancer | radiopharmaceutical | Phase 1 |
| CLR 121225 (CLR 225) | solid tumors (pancreatic, colorectal, breast models) | radiopharmaceutical | Pre-clinical |
| Other phospholipid drug conjugates (small molecule and peptide payloads) | oncology | small molecule | Pre-clinical |
Recent results and decisions
- Aug 13, 2026positive ASCO 2026 subset analysis of CLOVER WaM post-BTKi patients (n=24): ORR 87.5%, MRR 79.2%, 100% clinical benefit rate, median DoR 16 months; only Grade 3+ AEs were cytopenias.
Efficacy from the evaluable patients (n=24) included: 100% clinical benefit rate, 87.5% overall response rate (ORR), 79.2% MRR, partial response (PR) or better, median duration of response (DOR) of 16 months.
Filing - May 8, 2026met 12-month follow-up of CLOVER WaM (n=55): ORR 83.6%, MRR 61.8% (primary endpoint achieved), median DoR 17.8 months, median PFS 13.5 months.
The Company announced that 83.6% Overall Response Rate (“ORR”) and 61.8% Major Response Rate (“MRR”) were observed in the heavily pretreated population with median duration of response of 17.8 months.
Filing - Nov 13, 2025positive Interim CLOVER-2 Phase 1b data in pediatric high-grade glioma showed extended PFS and overall survival with a consistent, well-tolerated safety profile.
Results showed extended progression-free survival along with overall survival, and iopofosine I 131 was well tolerated and its toxicity profile was consistent with the Company’s previously reported safety data.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.